Stereotaxis, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $113.2M
- Price
- $1.13
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.74%
- Volume
- 337.0K
About
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Quick stats
Shares outstanding100.2M
Computed float80.9M
Float / shares80.8%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001289340
Websitehttps://www.stereotaxis.com
AI Summary
AI-generated1/15
minorneutraloperations update
Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026
Stereotaxis' digital and robotic portfolio, including the Synchrony lab display and the SynX cloud connectivity platform, will be featured at the Heart Rhythm Society's HRX conference in Atlanta on September 18-20, 2026.
Chairman and CEO David Fischel joins the main-stage panel 'Autonomous and Assistive EP Procedural Systems' on September 19 at 11:35 a.m. EDT, moderated by Dr. Peter Weiss with physician panelists Dr. Jim Cheung and Dr. Jennifer Silva.
Synchrony, which received FDA clearance earlier this year, is already in use at multiple clinical sites across the US and Europe; the release contains no new financial or clinical data.